Premium
REBACIN® as a noninvasive clinical intervention for high‐risk human papillomavirus persistent infection
Author(s) -
Yang Yi,
Meng YaLi,
Duan ShuMin,
Zhan ShaoBing,
Guan RuoLi,
Yue TianFu,
Kong LingHua,
Zhou Ling,
Deng LiuHong,
Huang Chao,
Wang Sheng,
Wang GuiYu,
Wu DaiFei,
Zhang ChunFa,
Chen Fei
Publication year - 2019
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.32344
Subject(s) - medicine , hpv infection , human papillomavirus , cervical cancer , oncology , genotyping , papillomaviridae , immunology , cancer , cancer research , biology , gene , genotype , biochemistry
The development of highly sensitive HPV‐genotyping tests has opened the possibility of treating HPV‐infected women before high‐grade lesions appear. The lack of efficient intervention for persistent high‐risk HPV infection necessitates the need for development of novel therapeutic strategy. Here we demonstrate that REBACIN®, a proprietary antiviral biologics, has shown potent efficacy in the clearance of persistent HPV infections. Two independent parallel clinical studies were investigated, which a total of 199 patients were enrolled and randomly divided into a REBACIN®‐test group and a control group without treatment. The viral clearance rates for the REBACIN® groups were 61.5% (24/39) and 62.5% (35/56), respectively, for the two independent parallel studies. In contrast, the nontreatment groups showed self‐clearance rates at 20.0% (8/40) and 12.5% (8/64). We further found that REBACIN® was able to significantly repress the expression of HPV E6 and E7 oncogenes in TC‐1 and Hela cells. The two viral genes are well known for the development of high‐grade premalignancy lesion and cervical cancer. In a mouse model, REBACIN® was indicated to notably suppress E6/E7‐induced tumor growth, suggesting E6 and E7 oncogenes as a potential target of REBACIN®. Taken together, our studies shed light into the development of a novel noninvasive therapeutic intervention for clearance of persistent HPV infection with significant efficacy.